BRAF and benign neoplasm: In the second blind-label cohort, overall concordance was consistent in 85.7% of cases whereas 10.7% of cases had a histologic diagnosis of malignancy without the BRAF mutation, and 3.6% had a histologic diagnosis of a benign neoplasm and the BRAF mutation.